Immuron granted patent for anti-influenza product

By Staff Writers
Wednesday, 02 March, 2011

Melbourne-based Immuron scored a win today with the granting of an Australian patent for its influenza prevention product, Imm-255.

The patent, issued by the Australian Patents Office, provides protection through to 2028.

Imm-255 uses dairy-derived polyclonal influenza-specific antibodies, which are applied to oral and respiratory surfaces.

The antibodies have to date shown positive results in treating and preventing influenza in mice and ferrets, including treating H1N1.

Once animal trials have concluded, Immuron intends to proceed towards clinical trials in humans.

Immuron's (ASX:IMC) stock dropped $0.004 to 7.1c in morning trading.

Related News

Does exercise really extend lifespan? It's complicated

Physical activity is seen as a way to extend the human lifespan, but the benefits of physical...

Nature helps to relieve physical pain

Experiencing nature, even in the form of watching nature videos, can alleviate acute physical pain.

SEQ koala population carries immunity to retrovirus

Koalas from a population north of the Brisbane River appear to have evolved a unique genomic...


  • All content Copyright © 2025 Westwick-Farrow Pty Ltd